Merck & Company said early Monday it has launched its tumor necrosis factor blocker Renflexis in the U.S., a biosimilar of the originator biologic medicine Remicade (infliximab). Renflexis was approved by the U.S. Food and Drug Administration on April 21 for Crohn’s disease, Pediatric Crohn’s disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis.
Renflexis is the first medicine available in the U.S. under a global biosimilars development and commercialization agreement between Merck and Samsung Bioepis Co. Ltd., the company said in a press release. Renflexis will be introduced in the U.S. at a list price (wholesaler acquisition cost) of $753.39, representing a 35% discount to the current list price of Remicade, its reference product. Wholesaler acquisition costs do not include discounts that may be paid on the products.